Qelbree represents a development in ADHD pharmacodynamics1
Qelbree is the first and only ADHD nonstimulant with a multimodal pharmacodynamic profile1-4*
Qelbree integrates NE reuptake inhibition with serotonin (5‑HT2C) receptor modulation via partial agonism1
Qelbree interacts with the brain in multiple ways in the prefrontal cortex (PFC).1,5
Qelbree
- NET inhibition1†
Qelbree binds to and inhibits NET (norepinephrine transporters)1 - Serotonin 5-HT2C receptor partial agonist1
Qelbree is the only ADHD treatment with serotonin receptor pharmacodynamics approved in FDA product labeling1-4, 6-9* - Qelbree is not a
controlled substance1
Atomoxetine
- NET inhibition2
Guanfacine
- Selective Alpha-2A Adrenergic Receptor Agonist3
Psychostimulants
- NET inhibition8,9
- DAT inhibition8,9
Psychostimulants impact DAT in the areas of the brain associated with addiction and are controlled substances.10,11
*The pharmacodynamic activity of viloxazine is based on non-clinical studies and the clinical significance of the data is unknown. The mechanism of action of viloxazine in the treatment of ADHD is unclear; however, it is thought to be through inhibiting the reuptake of norepinephrine.1
†Inhibition of NET increases NE levels in the PFC.5
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; DAT, dopamine transporter; NET, norepinephrine transporter.
What makes Qelbree different?
Take a closer look at Qelbree
Hear directly from Dr. Ann Childress and Dr. Andy Cutler as they share their perspectives on Qelbree’s pharmacodynamics and discuss the evolving science of ADHD.
The healthcare providers featured in this video were compensated for their participation.
Discover more:
Stay informed
Get Qelbree email updates, savings information, and links to helpful resources for you and your patients.